Written patient information about triple-marker screening: a randomized, controlled trial
Glazier R, Goel V, Holzapfel S, Summers A, Pugh P, Yeung M. Obstet Gynecol. 1997; 90(5):769-74.
Publications
Prostate cancer screening in the midst of controversy: Canadian men’s knowledge, beliefs, utilization, and future intentions
Mercer SL, Goel V, Levy IG, Ashbury FD, Iverson DC, Iscoe NA. Can J Public Health. 1997; 88(5):327-32.
Enthusiasm or uncertainty: small area variations in the use of mammography services in Ontario, Canada
Goel V, Iron K, Williams JI. J Epidemiol Community Health. 1997; 51(4):378-82.
Socio-economic status and visits to physicians by adults in Ontario, Canada
McIsaac W, Goel V, Naylor D. J Health Serv Res Policy. 1997; 2(2):94-102.
The rise of tamoxifen: temporal and geographical trends of tamoxifen use in Ontario
Palda VA, Goel V, Sawka CA. Breast Cancer Res Treat. 1997; 43(1):33-41.
The association between population-based treatment guidelines and adjuvant therapy for node-negative breast cancer
Sawka C, Olivotto I, Coldman A, Goel V, Holowaty E, Hislop TG. Br J Cancer. 1997; 75(10):1534-42.
Compliance with practice guidelines for node-negative breast cancer
Olivotto IA, Coldman AJ, Hislop TG, Trevisan CH, Kula J, Goel V, Sawka C. J Clin Oncol. 1997; 15(1):216-22.
Development of an instrument to measure cancer screening knowledge, attitudes and behaviours
Kindree T, Ashbury FD, Goel V, Levy I, Lipskie T, Futcher R. Chronic Dis Can. 1997; 18(4):168-75.
Patterns of initial management of node-negative breast cancer in two Canadian provinces
Goel V, Olivotto I, Hislop TG, Sawka C, Coldman A, Holowaty EJ. CMAJ. 1997; 156(1):25-35.